64Cu2+-based PET imaging was also used in a clinical study involving MM-302, a PEGylated liposomal formulation of doxorubicin with targeting activity toward HER2 (a growth factor receptor overexpressed in many mammary carcinomas) for the treatment of breast cancer (Lee et al., 2017). Here, ERBB2 is linked to breast carcinoma.